| Title |
Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
|
|---|---|
| Published in |
Drug Design, Development and Therapy, June 2010
|
| DOI | 10.2147/dddt.s6627 |
| Pubmed ID | |
| Authors |
Clemens Warnke, Heinz Wiendl, Hans-Peter Hartung, Olaf Stüve, Bernd C Kieseier |
| Abstract |
Orally available disease-modifying drugs for relapsing-remitting multiple sclerosis (MS) represent an unmet need for this chronic and debilitating disease. Among 5 currently investigated drugs at phase 3 clinical stage, promising efficacy data for fingolimod and oral cladribine have recently been published. However, benefits need to be weighed against the risks to define the role of these compounds within current treatment regimens. In this review, data on the efficacy of a promising compound, oral cladribine, are discussed and balanced with known and anticipated risks in a postmarketing era, and finally gives an outlook on the potential place of this drug in treatment algorithms for MS in the future. |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Uruguay | 1 | 2% |
| Italy | 1 | 2% |
| Unknown | 41 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 16% |
| Student > Master | 6 | 14% |
| Student > Ph. D. Student | 5 | 11% |
| Student > Bachelor | 5 | 11% |
| Other | 5 | 11% |
| Other | 11 | 25% |
| Unknown | 5 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 32% |
| Agricultural and Biological Sciences | 8 | 18% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
| Neuroscience | 3 | 7% |
| Chemistry | 2 | 5% |
| Other | 5 | 11% |
| Unknown | 9 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 December 2016.
All research outputs
#5,339,368
of 25,374,917 outputs
Outputs from Drug Design, Development and Therapy
#360
of 2,268 outputs
Outputs of similar age
#22,033
of 105,104 outputs
Outputs of similar age from Drug Design, Development and Therapy
#2
of 5 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 105,104 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.